Table 1 Clinicopathological characteristics of 113 primary OCCCs.
Characteristics | OCCC (N = 113) | |
|---|---|---|
Age (years) | ||
range | 34–82 | |
mean/median | 60.5/62 | |
FIGO | (N = 104) | |
IA | 38 (37%) | |
IB | 1 (1%) | |
IC | 36 (35%) | |
II | 8 (8%) | |
III | 20 (19%) | |
IV | 1 (1%) | |
NA | 9 | |
T stage | (N = 105) | |
low (T1 + T2) | 87 (83%) | |
high (T3) | 18 (17%) | |
NA | 8 | |
N stage | (N = 101) | |
N0 | 48 (48%) | |
N1 | 7 (7%) | |
Nx | 46 (46%) | |
NA | 12 | |
M stage | (N = 101) | |
M0 | 6 (6%) | |
M1 | 1 (1%) | |
Mx | 94 (93%) | |
NA | 12 | |
Neoadjuvant therapy | (N = 81) | |
No | 77 | |
Yes | 4 | |
NA | 32 | |
Adjuvant therapy | (N = 95) | |
No | 11 (12%) | |
Yes | 84 (88%) | |
Chemotherapy | 83 (99%) | |
Chemotherapy and targeted treatment | 1 (1%) | |
NA | 18 | |
Lymphadenectomy | (N = 108) | |
No | 53 (49%) | |
Yes | 55 (51%) | |
NA | 5 | |
Recurrence | (N = 99) | |
No | 68 (69%) | |
Yes | 31 (31%) | |
Local (pelvic) | 19 (61%) | |
Distant | 11 (35%) | |
Combined | 1 (3%) | |
NA | 14 | |
Survival status (FU mean/median in months) | (N = 99) | |
NED (56/52) | 58 (59%) | |
AWD (44/29) | 18 (18%) | |
DOD (32/25) | 10 (10%) | |
DTC (1/1) | 3 (3%) | |
DUC/DOC (31/28) | 10 (10%) | |
NA | 14 |